Clinical Trials
4 trialsNCT04595747 2026-05-22
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03762122 2022-11-09
Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
Swiss Cancer Institute
Phase 2 Terminated
NCT04125693 2022-04-01
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
Bayer
Phase 2 Completed
NCT04040725 2019-12-17
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Dana-Farber Cancer Institute
Phase 2 Withdrawn